Kids v Cancer launches Compassionate Use Navigator tools

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

KIDS V CANCER launched the Compassionate Use Navigator for the pediatric oncology community that provides up-to-date information on the compassionate use application process.

The Compassionate Use Navigator provides: an option for physicians to request help from Compassionate Use Navigator staff in completing a compassionate use application; step-by-step instructions on how to apply for compassionate use, including forms and templates; assistance in identifying points of contact at drug companies; and information on FDA and IRB rules for obtaining compassionate use medications.

In addition, the navigator aims to fill knowledge gaps about compassionate use by collecting data on the numbers and outcomes of applications. This data will lay the groundwork for developing next steps to improve access to drugs for those in dire need.

Table of Contents

YOU MAY BE INTERESTED IN

When our hematological malignancy testing pilot project began in Eldoret, Kenya, there seemed to be a mismatch in relation to progress in healthcare. The region, like much of sub-Saharan Africa, had been focusing on combatting infectious diseases such as HIV and malaria—which was much-needed—yet cancer care was under-resourced. 
Artificial intelligence is rapidly transforming biomedical research and healthcare. Large language models, foundation models, and AI agents are increasingly being deployed to assist with data interpretation, literature review, clinical decision support, and translational research. 
In modern oncology, important insights from clinical trials often emerge years after initial publication. As new therapies extend survival and transition more patients into long-term remissions, clinicians and researchers are increasingly looking beyond initial response rates to understand durability, long-term safety, and even the possibility of a cure. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login